[{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Undisclosed","graph2":"Phase I","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Undisclosed","graph2":"Phase I","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Undisclosed","graph2":"Phase I","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Insert","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Insert","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Insert","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Insert","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ring","sponsorNew":"Johnson & Johnson \/ ViiV Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ ViiV Healthcare"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ring","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Microbicide Trials Network | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Microbicide Trials Network | National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Microbicide Trials Network | National Institutes of Health"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Gilead Sciences"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"National Institutes of Health | National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ National Institutes of Health | National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ National Institutes of Health | National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Gansu Provincial Maternal and Child Health Care Hospital | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Gansu Provincial Maternal and Child Health Care Hospital | National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"International Partnership for Microbicides \/ Gansu Provincial Maternal and Child Health Care Hospital | National Institutes of Health"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ National Institutes of Health"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases | National Institute of Mental Health | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases | National Institute of Mental Health | National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"International Partnership for Microbicides \/ Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases | National Institute of Mental Health | National Institutes of Health"}]
Find Clinical Drug Pipeline Developments & Deals for Dapivirine
Details :
Dapivirine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.
Details :
The dapivirine ring received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use through EU-M4all procedure, Prequalification from the World Health Organization (WHO), a WHO recommendation for use and ...
Details :
Dapivirine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hemorrhage.
Details :
EMA’s human medicines committee has adopted a positive opinion for Dapivirine Vaginal Ring used to reduce the risk of infection with the human immunodeficiency virus type 1 (HIV-1), in combination with safer sex practices when oral pre-exposure prophyl...
Sponsor :
Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases | National Institute of Mental Health | National Institutes of Health
Details :
Dapivirine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Contraception.
Sponsor :
Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Allergy and Infectious Diseases | National Institute of Mental Health | National Institutes of Health
Details :
Dapivirine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.
Details :
Dapivirine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.
Details :
Dapivirine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.
Details :
Dapivirine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.
Details :
Dapivirine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of HIV Infections.
Reset All
